title: Employing Central Composite Design for Evaluation of Biomass Production by Fusarium venenatum: In Vivo Antioxidant and Antihyperlipidemic Properties.
abstract: The present study deals with the cost effective production of biomass from Fusarium venenatum using different carbon sources (cane sugar, brown sugar, malt and fructose). Optimization of selected carbon sources and seed size using Central Composite Response Surface Design (CCRSD) indicated that sucrose (1.64 g/100 mL) and seed size (10% v/v) were optimal in maximizing biomass yield (0.5602 g/100 mL, p < 0.0001) and protein yield (49.99%, p < 0.01) of Fusarium venenatum. The acetonitrile and methanolic extracts of biomass showed promising antioxidant activity (DPPH assay, 59.7 and 51.9% respectively, 250 μg/mL). The mycoprotein, in the Triton-X 100-induced hyperlipidemic model in rats, exhibited significant reduction of serum lipids levels (p < 0.01 at 100, 200 and 400 mg/kg body weight) with significant increase in HDL level. It also exhibited antibacterial activity against S. aureus. LC-MS analysis of ACN extract of biomass showed two major peaks (Compound 3: m/e 701.4941 and Compound 2: m/e 651.4984). Spectral matching with standard MS libraries indicated that compound 3 may be structurally similar to sterol glycoside (m/e 716.99) with absence of methyl group. Also, compound 2 may be cholest-5-en-3-ol (3β)-, 9-octadecenoate. These results showed that Fusarium venenatum can act as a source of natural antioxidant along with acting as a valuable protein source. It may also prove to be beneficial in treatment of hyperlipidemia and other cardiovascular conditions. Further bioactivity-guided fractionation and isolation will help to obtain bioactives that may serve as leads for design of new class of therapeutic agents.
authors.affiliation: Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, MS, 411 018, India. dypharmachem@yahoo.co.in.
authors.forename: Asha Byju
authors.initials: AB
authors.lastname: Thomas
authors.affiliation: Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, MS, 411 018, India.
authors.forename: Trupti Dattatray
authors.initials: TD
authors.lastname: Shetane
authors.affiliation: Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, MS, 411 018, India.
authors.forename: Ranu Goutam
authors.initials: RG
authors.lastname: Singha
authors.affiliation: Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, MS, 411 018, India.
authors.forename: Rabindra K
authors.initials: RK
authors.lastname: Nanda
authors.affiliation: Department of Pharmaceutical Chemistry, Dr. D.Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, MS, 411 018, India.
authors.forename: Sushilkumar S
authors.initials: SS
authors.lastname: Poddar
authors.affiliation: Peptide- Formulation Development (NDDS), Sun Pharmaceutical Industries Ltd, Vadodara, India.
authors.forename: Ajinath
authors.initials: A
authors.lastname: Shirsat
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology; D000975:Antioxidants / Q000737:chemistry / Q000494:pharmacology; D018533:Biomass; D045424:Complex Mixtures / Q000737:chemistry / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical; D005670:Fusarium / Q000737:chemistry / Q000254:growth & development; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013211:Staphylococcus aureus / Q000254:growth & development
chemical_list: D000900:Anti-Bacterial Agents; D000975:Antioxidants; D045424:Complex Mixtures; D000960:Hypolipidemic Agents
keywords: Antihyperlipidemic activity; Antimicrobial; Antioxidant; Central composite response surface design; LC-MS analysis; Protein source